# A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood

> **NCT05738291** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 67 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1839100
- **DRUG:** Placebo matching BI 1839100
- **DRUG:** midazolam
- **DRUG:** digoxin
- **DRUG:** rosuvastatin

## Key facts

- **NCT ID:** NCT05738291
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-01
- **Primary completion:** 2024-06-14
- **Final completion:** 2024-06-14
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05738291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05738291, "A Study in Healthy Men to Test How Well Multiple Doses of BI 1839100 Are Tolerated and How BI 1839100 Influences the Amount of Other Medicines in the Blood". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05738291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*